|
Table 3: additional information from SMS-Reminder for vaccination research findings in Africa: results |
|||||||
|
Country |
Kenya |
Nigeria |
Zimbabwe |
Burkina Faso |
Senegal |
||
|
Author |
Gibson et al. |
Haji et al. |
Brown et al. |
Eze, Adeleye |
Bangure et al. |
Schlumberger et al. |
Thiaw et al. |
|
Primary Outcome Measure |
Immunization coverage after 12 months (FIC) |
Dropout rate for pentavalent 3rd dose |
RI completion rate at 12 months of age |
DPT3 timely completion rate |
Immunization coverage at 6 wks, 10 wks and 14 wks |
Immunization completeness for pentavalent 3rd dose + OPV + rotavirus |
Vitamin A supplement coverage |
|
Outcome Result Based on Primary Measure (intervention group) |
86% (SMS only), 86% (SMS+75 KES), 90% (SMS+200KES) |
4% (SMS), 16% (sticker) |
98.6% (SMS), 70% (PHCIPT), 97.3% (SMS+PHCIPT) |
69% (SMS) |
97% at 6 wks (SMS), 96% at 10 wks (SMS), 95% at 14 wks (SMS) |
73.3% for OPV1 (SMS), 71.3% for OPV2 (SMS), 60.3% for OPV3 (SMS) |
67.7% (SMS) |
|
Outcome Result Based on Primary Measure (control) |
82% |
17% |
57.30% |
60% |
82% at 6 wks, 80% at 10 wks, 75% at 14 wks |
55.7% for OPV1, 53.6% for OPV2, 42.3% for OPV3 |
6% |
|
Baseline |
N/A |
13% |
N/A |
58% |
74% at 6 wks, 84% at 10 wks, 74% at 14 wks |
N/A |
8.8% (intervention group) 3% (control group) |
|
Confidence Interval or p-value |
p=0.045 (SMS only), p<0.0001 (SMS+75 KES), p<0.0001 (SMS+200KES) |
CI 0.04-0.8 (SMS) |
CI 1.50-1.98 (SMS), CI 1.03-1.45(PHCIPT), CI 1.47-1.95 (SMS+PHCIPT) |
p=0.009, CI 1.103-1.955 (SMS) |
p<0.001 (SMS) |
p<0.001 for OPV1 (SMS), p<0.001 for OPV2 (SMS), p<0.001 for OPV3 (SMS) |
N/A |